by University of California, Los Angeles Credit: Pixabay/CC0 Public Domain Research led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to a type of immunotherapy called PD-1 checkpoint blockade in patients with advanced melanoma depended on whether or not they had previously received another immunotherapy—CTLA-4 blockade—as well as other factors. Their findings, based on...
